

Yanyan Lou

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/578151/publications.pdf>

Version: 2024-02-01

47
papers

3,363
citations

279798

23
h-index

243625

44
g-index

47
all docs

47
docs citations

47
times ranked

5371
citing authors

#	ARTICLE	IF	CITATIONS
1	Next generation of immune checkpoint therapy in cancer: new developments and challenges. <i>Journal of Hematology and Oncology</i> , 2018, 11, 39.	17.0	597
2	Epithelialâ€“Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma. <i>Clinical Cancer Research</i> , 2016, 22, 3630-3642.	7.0	353
3	Next generation of immune checkpoint inhibitors and beyond. <i>Journal of Hematology and Oncology</i> , 2021, 14, 45.	17.0	293
4	The Genomic Landscape and Pharmacogenomic Interactions of Clock Genes in Cancer Chronotherapy. <i>Cell Systems</i> , 2018, 6, 314-328.e2.	6.2	183
5	Cancer immunotherapy beyond immune checkpoint inhibitors. <i>Journal of Hematology and Oncology</i> , 2018, 11, 8.	17.0	174
6	Emerging therapeutic agents for advanced non-small cell lung cancer. <i>Journal of Hematology and Oncology</i> , 2020, 13, 58.	17.0	161
7	Characterization of hypoxia-associated molecular features to aid hypoxia-targeted therapy. <i>Nature Metabolism</i> , 2019, 1, 431-444.	11.9	158
8	Targeted therapy in advanced non-small cell lung cancer: current advances and future trends. <i>Journal of Hematology and Oncology</i> , 2021, 14, 108.	17.0	127
9	Plasmacytoid Dendritic Cells Synergize with Myeloid Dendritic Cells in the Induction of Antigen-Specific Antitumor Immune Responses. <i>Journal of Immunology</i> , 2007, 178, 1534-1541.	0.8	122
10	Dendritic Cells Strongly Boost the Antitumor Activity of Adoptively Transferred T Cells In vivo. <i>Cancer Research</i> , 2004, 64, 6783-6790.	0.9	116
11	Cost Effectiveness of Pembrolizumab vs. Standard-of-Care Chemotherapy as First-Line Treatment for Metastatic NSCLC that Expresses High Levels of PD-L1 in the United States. <i>Pharmacoeconomics</i> , 2017, 35, 831-844.	3.3	115
12	Comprehensive Characterization of Alternative Polyadenylation in Human Cancer. <i>Journal of the National Cancer Institute</i> , 2018, 110, 379-389.	6.3	111
13	Peripheral blood biomarkers correlate with outcomes in advanced non-small cell lung Cancer patients treated with anti-PD-1 antibodies. , 2018, 6, 129.		95
14	Sex Differences in Tolerability to Anti-Programmed Cell Death Protein 1 Therapy in Patients with Metastatic Melanoma and Non-Small Cell Lung Cancer: Are We All Equal?. <i>Oncologist</i> , 2019, 24, e1148-e1155.	3.7	81
15	Emerging therapeutic agents for lung cancer. <i>Journal of Hematology and Oncology</i> , 2016, 9, 138.	17.0	77
16	Antitumor Activity Mediated by CpG. <i>Journal of Immunotherapy</i> , 2011, 34, 279-288.	2.4	59
17	Association Between Sex and Immune-Related Adverse Events During Immune Checkpoint Inhibitor Therapy. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1396-1404.	6.3	56
18	Cost-effectiveness of pembrolizumab versus docetaxel for the treatment of previously treated PD-L1 positive advanced NSCLC patients in the United States. <i>Journal of Medical Economics</i> , 2017, 20, 140-150.	2.1	44

#	ARTICLE	IF	CITATIONS
19	MHC class II restricted neoantigen peptides predicted by clonal mutation analysis in lung adenocarcinoma patients: implications on prognostic immunological biomarker and vaccine design. <i>BMC Genomics</i> , 2018, 19, 582.	2.8	42
20	Brain metastases from non-small cell lung cancer with EGFR or ALK mutations: A systematic review and meta-analysis of multidisciplinary approaches. <i>Radiotherapy and Oncology</i> , 2020, 144, 165-179.	0.6	42
21	Germline Mutation of T790M and Dual/Multiple EGFR Mutations in Patients With Lung Adenocarcinoma. <i>Clinical Lung Cancer</i> , 2016, 17, e5-e11.	2.6	39
22	Association of antibiotic treatment with immune-related adverse events in patients with cancer receiving immunotherapy. , 2022, 10, e003779.		34
23	Immunotherapy in Non-Small Cell Lung Cancer With Actionable Mutations Other Than EGFR. <i>Frontiers in Oncology</i> , 2021, 11, 750657.	2.8	32
24	Agonistic Antibody to CD40 Boosts the Antitumor Activity of Adoptively Transferred T Cells In Vivo. <i>Journal of Immunotherapy</i> , 2012, 35, 276-282.	2.4	31
25	Survival trends among non-small cell lung cancer patients over a decade: impact of initial therapy at academic centers. <i>Cancer Medicine</i> , 2018, 7, 4932-4942.	2.8	25
26	Immunotherapies targeting stimulatory pathways and beyond. <i>Journal of Hematology and Oncology</i> , 2021, 14, 78.	17.0	23
27	Association of Race, Socioeconomic Factors, and Treatment Characteristics With Overall Survival in Patients With Limited-Stage Small Cell Lung Cancer. <i>JAMA Network Open</i> , 2021, 4, e2032276.	5.9	22
28	Influence of Sociodemographic Factors on Treatment Decisions in Non-small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2020, 21, e115-e129.	2.6	19
29	Hypereosinophilia in a patient with metastatic non-small-cell lung cancer treated with antiprogrammed cell death 1 (anti-PD-1) therapy. <i>Immunotherapy</i> , 2019, 11, 577-584.	2.0	18
30	Mogamulizumab in Combination with Nivolumab in a Phase I/II Study of Patients with Locally Advanced or Metastatic Solid Tumors. <i>Clinical Cancer Research</i> , 2022, 28, 479-488.	7.0	16
31	Molecular basis of antibody binding to mucin glycopeptides in lung cancer. <i>International Journal of Oncology</i> , 2016, 48, 587-594.	3.3	13
32	Profiling of immune features to predict immunotherapy efficacy. <i>Innovation(China)</i> , 2021, 3, 100194.	9.1	13
33	A Phase Ib/II Study of Pepinemab in Combination with Avelumab in Advanced Non-small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 3630-3640.	7.0	11
34	Correlation between immunohistochemistry and RICTOR fluorescence in situ hybridization amplification in small cell lung carcinoma. <i>Human Pathology</i> , 2019, 93, 74-80.	2.0	10
35	Role of Immune Checkpoint Inhibitor Therapy in Advanced EGFR-Mutant Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 751209.	2.8	10
36	Humoral Responses After SARS-CoV-2 mRNA Vaccination and Breakthrough Infection in Cancer Patients. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2022, 6, 120-125.	2.4	10

#	ARTICLE	IF	CITATIONS
37	Immunogenicity of Del19 EGFR mutations in Chinese patients affected by lung adenocarcinoma. <i>BMC Immunology</i> , 2019, 20, 43.	2.2	6
38	Effects of Age and Immune Landscape on Outcome in HER2-Positive Breast Cancer in the NCCTG N9831 (Alliance) and NSABP B-31 (NRG) Trials. <i>Clinical Cancer Research</i> , 2019, 25, 4422-4430.	7.0	6
39	BRAF p.V600E associated poly-neoplastic syndrome. <i>Rare Tumors</i> , 2021, 13, 203636132110129.	0.6	4
40	Immune-related hematologic adverse events in the context of immune checkpoint inhibitor therapy. <i>American Journal of Hematology</i> , 2021, 96, E362-E367.	4.1	4
41	Patients with high-grade alectinib-induced skin rash: How do we desensitize these patients? A case report and review of literature. <i>SAGE Open Medical Case Reports</i> , 2020, 8, 2050313X2096689.	0.3	3
42	Carbon ion radiotherapy in the management of non-small cell lung cancer. <i>Precision Radiation Oncology</i> , 2022, 6, 69-74.	1.1	3
43	Survival of Black and White Patients With Stage IV Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 773958.	2.8	2
44	Post-operative radiation therapy in locally advanced non-small cell lung cancer and the impact of sequential versus concurrent chemotherapy. <i>Translational Lung Cancer Research</i> , 2018, 7, S171-S175.	2.8	1
45	Immune-Related Hematologic Adverse Events in the Context of Checkpoint Inhibitors. <i>Blood</i> , 2020, 136, 31-32.	1.4	1
46	Interim subgroup analysis for response by PD-L1 status of CLASSICAL-Lung, a phase Ib/II study of pepinemab (VX15/2503) in combination with avelumab in advanced NSCLC. <i>Journal of Clinical Oncology</i> , 2020, 38, 3011-3011.	1.6	1
47	Epidemiologic and Clinical Analysis of Tumor Mutational Burden (TMB) in Acute Myeloid Leukemia (AML): Exome Sequencing Study of the Mayo Clinic AML Epidemiology Cohort (MCAEC). <i>Blood</i> , 2021, 138, 3437-3437.	1.4	0